Aspen Aerogels, Inc. (NYSE:ASPN) Stock Holdings Lessened by BNP Paribas Financial Markets

BNP Paribas Financial Markets decreased its position in shares of Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) by 82.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 18,189 shares of the construction company's stock after selling 86,832 shares during the period. BNP Paribas Financial Markets' holdings in Aspen Aerogels were worth $504,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Point72 Hong Kong Ltd acquired a new position in Aspen Aerogels during the second quarter worth approximately $84,000. nVerses Capital LLC acquired a new position in Aspen Aerogels during the second quarter worth approximately $95,000. Quent Capital LLC acquired a new position in Aspen Aerogels during the third quarter worth approximately $118,000. Point72 DIFC Ltd acquired a new position in Aspen Aerogels during the second quarter worth approximately $121,000. Finally, Public Employees Retirement Association of Colorado acquired a new position in Aspen Aerogels during the second quarter worth approximately $145,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Aspen Aerogels Stock Down 0.1 %

NYSE ASPN traded down $0.01 during trading hours on Friday, reaching $13.14. 1,058,666 shares of the company traded hands, compared to its average volume of 1,625,721. Aspen Aerogels, Inc. has a 12 month low of $10.75 and a 12 month high of $33.15. The company has a current ratio of 2.93, a quick ratio of 2.48 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $1.08 billion, a PE ratio of 1,315.32 and a beta of 2.11. The company has a 50 day moving average of $17.37 and a two-hundred day moving average of $22.99.

Insider Buying and Selling at Aspen Aerogels

In other news, CEO Donald R. Young sold 63,355 shares of the firm's stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $30.03, for a total value of $1,902,550.65. Following the transaction, the chief executive officer now directly owns 483,640 shares in the company, valued at approximately $14,523,709.20. This trade represents a 11.58 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Barclays dropped their price objective on shares of Aspen Aerogels from $27.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday, November 12th. TD Cowen increased their price objective on shares of Aspen Aerogels from $36.00 to $41.00 and gave the stock a "buy" rating in a research report on Tuesday, August 20th. StockNews.com raised shares of Aspen Aerogels to a "sell" rating in a research report on Wednesday, November 13th. Piper Sandler dropped their price objective on shares of Aspen Aerogels from $36.00 to $33.00 and set an "overweight" rating for the company in a research report on Tuesday, October 22nd. Finally, Roth Mkm dropped their price objective on shares of Aspen Aerogels from $36.00 to $31.00 and set a "buy" rating for the company in a research report on Friday, November 8th. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $28.70.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.